- Home
- COE vs RVPH Comparison
COE vs RVPH Comparison
Compare COE & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- RVPH
- Stock Information
- Founded
- COE 2011
- RVPH 2006
- Country
- COE Singapore
- RVPH United States
- Employees
- COE N/A
- RVPH N/A
- Industry
- COE Other Consumer Services
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- RVPH Health Care
- Exchange
- COE Nasdaq
- RVPH Nasdaq
- Market Cap
- COE 44.1M
- RVPH 35.1M
- IPO Year
- COE 2016
- RVPH N/A
- Fundamental
- Price
- COE $14.99
- RVPH $1.35
- Analyst Decision
- COE
- RVPH Strong Buy
- Analyst Count
- COE 0
- RVPH 4
- Target Price
- COE N/A
- RVPH $14.33
- AVG Volume (30 Days)
- COE 12.0K
- RVPH 812.1K
- Earning Date
- COE 08-23-2024
- RVPH 08-14-2024
- Dividend Yield
- COE N/A
- RVPH N/A
- EPS Growth
- COE N/A
- RVPH N/A
- EPS
- COE N/A
- RVPH N/A
- Revenue
- COE $35,705,000.00
- RVPH N/A
- Revenue This Year
- COE N/A
- RVPH N/A
- Revenue Next Year
- COE N/A
- RVPH N/A
- P/E Ratio
- COE N/A
- RVPH N/A
- Revenue Growth
- COE 66.41
- RVPH N/A
- 52 Week Low
- COE $6.00
- RVPH $0.60
- 52 Week High
- COE $19.75
- RVPH $6.80
- Technical
- Relative Strength Index (RSI)
- COE 58.44
- RVPH 65.90
- Support Level
- COE $13.16
- RVPH $0.85
- Resistance Level
- COE $15.14
- RVPH $1.05
- Average True Range (ATR)
- COE 1.07
- RVPH 0.14
- MACD
- COE 0.15
- RVPH 0.06
- Stochastic Oscillator
- COE 60.21
- RVPH 100.00
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.